Vanda Pharmaceuticals Inc. (VNDA) Form 8-K — Oct 28, 2026
Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8 million, up 24% year-over-year, driven by Fanapt momentum (+24% YoY) and the early NEREUS launch, while total operating expenses fell 18% sequentially to $93.3 million. Net loss was $22.6 million ($0.37 per diluted share), roughly flat versus a year ago. Cash, equivalents and marketable securities fell to $140.5 million, down $123.4 million from year-end 2025, as the company funded multiple Phase III programs and launch preparations. Management guided to full-year 2026 revenue above $240 million and expects opex to decline further.
Key figures
- Revenue
- 69815000
- Guidance
- Full year 2026 total revenue greater than $240 million
- Revenue Yoy
- 24% increase
- Total Assets
- 382327000
- Cash Position
- 140500000
- Pdufa date
- December 12, 2026 (Quimilza BLA for GPP)
- Total opex q3
- $93.3M (-18% vs Q2 2026, +7% YoY)
- Fanapt q3 sales
- $38.8M (+24% YoY)
- Nereus q3 sales
- $1.6M (+60% vs Q2 2026)
- Cash decrease q3
- $29.5M decrease in Q3
- Hetlioz q3 sales
- $21.7M (+21% YoY)
- Ponvory q3 sales
- $7.7M (+10% YoY)
- Cash decrease ytd
- $123.4M decrease from Dec 31, 2025
- Nine month revenue
- $172.1M (+8% YoY)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.